News
| 4 min read
Biogen’s $850 million move to secure full global rights to felzartamab highlights a deeper shift in how antibody-driven diseases are being understood and treated.
| 6 min read
Emerging data shows alpha synuclein may be present in the majority of neurodegenerative disease cases, reshaping how clinicians understand dementia and Parkinson’s.
| 5 min read
Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions.
| 5 min read
New hair loss treatments, company acquisitions, artificial neurons, and more led the news this week.
| 3 min read
Preclinical data show a first-in-class transdermal bicarbonate therapy increases tumor pH, reactivates T cells and slows bladder tumor growth in mice.
| 4 min read
Accent Therapeutics advances a KIF18A inhibitor, leveraging genomic instability to create druggable dependencies.
| 4 min read
The rise of iPSC-derived immune cells and CRISPR-based engineering is reshaping functional genomics, but protein-level validation has struggled to keep pace.
| 4 min read
Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer
| 3 min read
PRISM brings together three organizations to standardize and distribute patient-derived iPSC motor neuron models that better represent the biological diversity of ALS.
| 4 min read
New vaccines, monoclonal antibodies, and oral therapies offer hope against the growing threat of tick-borne infections.
| 4 min read
Marriage linked to lower cancer risk, pharma deals, and more led the news this week.
| 3 min read
A first-of-its-kind CAR T treatment helped a woman achieve year-long remission from three severe autoimmune diseases that resisted nine prior therapies.
